World Journal of Gastrointestinal Surgery

World J Gastrointest Surg 2024 June 27; 16(6): 1485-1955





Published by Baishideng Publishing Group Inc

WJGS

World Journal of Gastrointestinal Surgery

Contents

Monthly Volume 16 Number 6 June 27, 2024

EDITORIAL

1485	Has the open surgical approach in colorectal cancer really become uncommon?
	Cariati M, Brisinda G, Chiarello MM
1493	Intestinal Behçet's disease: A review of clinical diagnosis and treatment Liu Y, Gao F, Yang DQ, Jiao Y
1501	Non-operative management of rectal cancer: Highlighting the controversies <i>Emile SH, Wignakumar A</i>
1507	Current considerations for the surgical management of gallbladder adenomas <i>Pavlidis ET, Galanis IN, Pavlidis TE</i>
1513	Immunotherapy in gastric cancer with liver metastasis: Challenges and opportunities <i>Bardakçi M, Ergun Y</i>
1517	From the mathematical model to the patient: The scientific and human aspects of artificial intelligence in gastrointestinal surgery

Arredondo Montero J

MINIREVIEWS

1521 Laparoscopic right radical hemicolectomy: Central vascular ligation and complete mesocolon excision vs D3 lymphadenectomy - How I do it?

Yadav K

ORIGINAL ARTICLE

Case Control Study

1527 Perioperative outcomes of transvaginal specimen extraction laparoscopic total gastrectomy and conventional laparoscopic-assisted total gastrectomy

Zhang ZC, Wang WS, Chen JH, Ma YH, Luo QF, Li YB, Yang Y, Ma D

Retrospective Cohort Study

Optimal extent of lymphadenectomy improves prognosis and guides adjuvant chemotherapy in 1537 esophageal cancer: A propensity score-matched analysis

Tang JM, Huang SJ, Chen QB, Wu HS, Qiao GB

1548 Efficacy of laparoscopic low anterior resection for colorectal cancer patients with 3D-vascular reconstruction for left coronary artery preservation

Wang Y, Liu ZS, Wang ZB, Liu S, Sun FB



 1558 Robotic-assisted low anterior resection for rectal cancer shows similar clinical efficacy to laparoscopic surgery: A propensity score matched study <i>Long SX, Wang XN, Tian SB, Bi YF, Gao SS, Wang Y, Guo XB</i> 1571 Machine learning prediction model for gray-level co-occurrence matrix features of synchronous liver metastasis in colorectal cancer <i>Yang KF, Li SJ, Xu J, Zheng YB</i> 1582 Risk factors associated with intraoperative persistent hypotension in pancreaticoduodenectomy <i>Wang XJ, Xuan XC, Sun ZC, Shen S, Yu F, Li NN, Chu XC, Yin H, Hu YL</i> Retrospective Study 1592 Endoscopic ultrasound-guided biliary drainage <i>vs</i> percutaneous transhepatic bile duct drainage in the management of malignant obstructive jaundice <i>Zhu QQ, Chen BF, Yang Y, Zuo XY, Liu WH, Wang TT, Zhang Y</i> 1601 Clinical efficacy of Gamma Knife® combined with transarterial chemoembolization and immunotherapy in the treatment of primary liver cancer <i>Wang GF, Shu CX, Cai XD, Wang HB, Xu JH, Jia YQ</i> 1609 Identifying the risk factors for pancreatic fistula after laparoscopic pancreaticoduodenectomy in patients with pancreatic cancer <i>Xu H, Meng QC, Hua J, Wang W</i> 1618 Correlation between postoperative chemotherapy regimen and survival in patients with resectable gastric adenocarcinoma accompanied with vascular cancer thrombus <i>Yang ZF, Dong ZX, Dai CJ, Fu LZ, Yu HM, Wang YS</i> 1629 Gastroesophageal signet ring cell carcinoma morbidity and mortality: A retrospective review <i>Grinlinton M, Furkert C, Maurice A, Angelo N, Booth M</i> 	
Conten	Monthly Volume 16 Number 6 June 27, 2024
1558	Robotic-assisted low anterior resection for rectal cancer shows similar clinical efficacy to laparoscopic surgery: A propensity score matched study
	Long SX, Wang XN, Tian SB, Bi YF, Gao SS, Wang Y, Guo XB
1571	Machine learning prediction model for gray-level co-occurrence matrix features of synchronous liver metastasis in colorectal cancer
	Yang KF, Li SJ, Xu J, Zheng YB
1582	Risk factors associated with intraoperative persistent hypotension in pancreaticoduodenectomy
	Wang XJ, Xuan XC, Sun ZC, Shen S, Yu F, Li NN, Chu XC, Yin H, Hu YL
	Retrospective Study
1592	Endoscopic ultrasound-guided biliary drainage vs percutaneous transhepatic bile duct drainage in the management of malignant obstructive jaundice
	Zhu QQ, Chen BF, Yang Y, Zuo XY, Liu WH, Wang TT, Zhang Y
1601	Clinical efficacy of Gamma Knife® combined with transarterial chemoembolization and immunotherapy in
	the treatment of primary liver cancer
	Wang GF, Shu CX, Cai XD, Wang HB, Xu JH, Jia YQ
1609	Identifying the risk factors for pancreatic fistula after laparoscopic pancreaticoduodenectomy in patients with pancreatic cancer
	Xu H, Meng QC, Hua J, Wang W
1618	Correlation between postoperative chemotherapy regimen and survival in patients with resectable gastric adenocarcinoma accompanied with vascular cancer thrombus
	Yang ZF, Dong ZX, Dai CJ, Fu LZ, Yu HM, Wang YS
1629	Gastroesophageal signet ring cell carcinoma morbidity and mortality: A retrospective review
	Grinlinton M, Furkert C, Maurice A, Angelo N, Booth M
1637	Analysis of lymph node metastasis and survival prognosis in early gastric cancer patients: A retrospective study
	Liu DY, Hu JJ, Zhou YQ, Tan AR
1647	Clinical study of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hypertriglyceridemia- induced acute pancreatitis and acute biliary pancreatitis with persistent organ failure
	Xu MS, Xu JL, Gao X, Mo SJ, Xing JY, Liu JH, Tian YZ, Fu XF
1660	Tumor recurrence and survival prognosis in patients with advanced gastric cancer after radical resection with radiotherapy and chemotherapy
	Nie SF, Wang CY, Li L, Yang C, Zhu ZM, Fei JD
1670	Prediction and analysis of albumin-bilirubin score combined with liver function index and carcinoem- bryonic antigen on liver metastasis of colorectal cancer
	Wang ZM, Pan SP, Zhang JJ, Zhou J



Carta	World Journal of Gastrointestinal Surgery
Conter	Monthly Volume 16 Number 6 June 27, 2024
1681	Comparative analysis of the short and medium-term efficacy of the Da Vinci robot <i>versus</i> laparoscopic total mesangectomy for rectal cancer
	Gao WG, Shi W, Gong XC, Li ZW, Tuoheti Y
1691	How to apply ex-vivo split liver transplantation safely and feasibly: A three-step approach
	Zhao D, Xie QH, Fang TS, Zhang KJ, Tang JX, Yan X, Jin X, Xie LJ, Xie WG
1700	Clinical efficacy of laparoscopic cholecystectomy combined with endoscopic papillary balloon dilation in treatment of gallbladder stones with common bile duct stones: A retrospective study
	Liu HD, Zhang Q, Xu WS, Jin S
1709	Evaluation of oxaliplatin and tigio combination therapy in locally advanced gastric cancer
	Wang T, Zhang LY
1717	Lung ultrasound score evaluation of the effect of pressure-controlled ventilation volume-guaranteed on patients undergoing laparoscopic-assisted radical gastrectomy
	Tan J, Bao CM, Chen XY
1726	Effect of endoscopic sphincterotomy and endoscopic papillary balloon dilation endoscopic retrograde cholangiopancreatographies on the sphincter of Oddi
	Fu K, Yang YY, Chen H, Zhang GX, Wang Y, Yin Z
1734	Influence of reduced-port laparoscopic surgery on perioperative indicators, postoperative recovery, and serum inflammation in patients with colorectal carcinoma
	Wu HB, Liu DF, Liu YL, Wang XF, Cao YP
	Clinical Trials Study
1742	Clinical effect of spleen aminopeptide on improving liver function damage and immune function in children with infant hepatitis syndrome
	Fang XQ, Gan T, Wang LM
	Observational Study
1749	Observation of therapeutic effect of lamp irradiation combined with purple gromwell oil gauze on alleviating intestinal colic in patients
	Cen BZ, Chen YS, Li LP, Wu JW, Xie YF
	Randomized Controlled Trial
1756	Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer
	Guo JY, Zhao LL, Cai HJ, Zeng H, Mei WD
	Randomized Clinical Trial
1765	Effect of high-protein peptide-based formula compared with isocaloric isonitrogenous polymeric formula in critically ill surgical patient
	Sumritpradit P, Shantavasinkul PC, Ungpinitpong W, Noorit P, Gajaseni C



Contents

World Journal of Gastrointestinal Surgery

Monthly Volume 16 Number 6 June 27, 2024

Clinical and Translational Research

- 1775 Metabolic disorders and hepatitis: Insights from a Mendelian randomization study Liang LB, Liu XP, Mao TR, Su QL
- 1791 Analysis of cancer-specific survival in patients with metastatic colorectal cancer: A evidence-based medicine study

Zhou YJ, Tan ZE, Zhuang WD, Xu XH

1803 FDX1 as a novel biomarker and treatment target for stomach adenocarcinoma

Xie XZ, Zuo L, Huang W, Fan QM, Weng YY, Yao WD, Jiang JL, Jin JQ

Basic Study

1825 Peritoneal fluid indocyanine green test for diagnosis of gut leakage in anastomotic leakage rats and colorectal surgery patients

Huang Y, Li TY, Weng JF, Liu H, Xu YJ, Zhang S, Gu WL

SYSTEMATIC REVIEWS

Global geoepidemiology of gastrointestinal surgery rates in Crohn's disease 1835

> Weissman S, Aziz M, Bangolo A, Nagesh VK, Aung H, Mathew M, Garcia L, Chandar SA, Karamthoti P, Bawa H, Alshimari A, Kejela Y, Mehdi N, Joseph CA, Kodali A, Kumar R, Goyal P, Satheesha S, Nivedita F, Tesoro N, Sethi T, Singh G, Belal A, Intisar A, Khalid H, Cornwell S, Suresh SB, Ahmed K, Marole KK, Anand OP, Reshi RB, Mehta TI, Elias S, Feuerstein JD

META-ANALYSIS

1845 Compare clinical efficacy and safety of neoadjuvant therapy and neoadjuvant chemoradiotherapy for locally advanced rectal cancer: Meta-analysis

Wang Y, Yang Y, Liu QQ, Wang SZ

1857 Sarcopenia adversely impacts clinical outcomes in patients undergoing pancreaticoduodenectomy: A systematic review and meta-analysis

Zhang QH, Ma JD, Lu YM, Zhang RN, Zhao ZH, Li YT, Chen QP

1871 Comparison efficacy and safety of total laparoscopic gastrectomy and laparoscopically assisted total gastrectomy in treatment of gastric cancer

Li L, Liu DY, Leng J, Tao XM, Wu HQ, Zhu YP

1883 Application value of indocyanine green fluorescence imaging in guiding sentinel lymph node biopsy diagnosis of gastric cancer: Meta-analysis

Zhang QJ, Cao ZC, Zhu Q, Sun Y, Li RD, Tong JL, Zheng Q

SCIENTOMETRICS

1894 Visualizing the landscape of appendiceal tumor research after 2010: A bibliometric study Ji JN, Yin ZB



Contents

World Journal of Gastrointestinal Surgery

Monthly Volume 16 Number 6 June 27, 2024

CASE REPORT

1910	No-touch isolation technique in emergency pancreaticoduodenectomy for neoplastic hemorrhage: Two case reports and review of literature
	Cho A, Katagiri S, Ota M, Onizawa S, Higuchi R, Sugishita T, Niwa Y, Ishita T, Mouri T, Kato A, Iwata M
1918	Malignant myopericytoma originating from the colon: A case report
	Zhang HL, Zhang M, Guo JQ, Wu FN, Zhu JD, Tu CY, Lv XL, Zhang K
1926	Novel magnetic compression technique for the treatment of postoperative anastomotic stenosis in rectal cancer: A case report
	Zhang MM, Sha HC, Xue HR, Qin YF, Song XG, Li Y, Li Y, Deng ZW, Gao YL, Dong FF, Lyu Y, Yan XP
1933	Magnetic compression anastomosis to restore biliary tract continuity after obstruction following major abdominal trauma: A case report
	Zhang MM, Tao J, Sha HC, Li Y, Song XG, Muensterer OJ, Dong FF, Zhang L, Lyu Y, Yan XP
1939	Colo-colonic intussusception as a rare complication of colonoscopy with polypectomy: Two case reports
	Xiang SH, Xu GQ
1948	Resection of polyps involving the appendiceal orifice by combined endo-laparoscopic surgery: Two case reports
	Zhang YY, Lu JY, Wang Q, Yang AM

LETTER TO THE EDITOR

Evaluating bacterial contamination and surgical site infection risks in intracorporeal anastomosis: Role of 1953 bowel preparation

Lee J

Contents

Monthly Volume 16 Number 6 June 27, 2024

ABOUT COVER

Peer Reviewer of World Journal of Gastrointestinal Surgery, Deven Juneja, DNB, FNB, EDIC, FCCP, Director, Department of Critical Care Medicine, Max Super Speciality Hospital, New Delhi 110017, India. devenjuneja@gmail.com

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Surgery (WJGS, World J Gastrointest Surg) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, etc.

INDEXING/ABSTRACTING

The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports[®] cites the 2023 journal impact factor (JIF) for WJGS as 1.8; JIF without journal self cites: 1.7; 5-year JIF: 1.9; JIF Rank: 123/290 in surgery; JIF Quartile: Q2; and 5-year JIF Quartile: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Zi-Hang Xu; Production Department Director: Xiang Li; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Gastrointestinal Surgery	https://www.wignet.com/bpg/gcrinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 1948-9366 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
November 30, 2009	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Peter Schemmer	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/1948-9366/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE June 27, 2024	STEPS FOR SUBMITTING MANUSCRIPTS https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2024 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



NU

World Journal of Gastrointestinal Surgery

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Surg 2024 June 27; 16(6): 1775-1790

DOI: 10.4240/wjgs.v16.i6.1775

ISSN 1948-9366 (online)

ORIGINAL ARTICLE

Clinical and Translational Research

Metabolic disorders and hepatitis: Insights from a Mendelian randomization study

Ling-Bo Liang, Xiang-Ping Liu, Ting-Rui Mao, Qiao-Li Su

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification Scientific Quality: Grade C Novelty: Grade B Creativity or Innovation: Grade B Scientific Significance: Grade B

P-Reviewer: Patra P, India

Received: March 12, 2024 Revised: April 30, 2024 Accepted: May 17, 2024 Published online: June 27, 2024 Processing time: 110 Days and 2.4 Hours



Ling-Bo Liang, Ting-Rui Mao, Qiao-Li Su, General Practice Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Xiang-Ping Liu, Department of Primary Health Care, The Fourth People's Hospital of Dazhu County, Dazhou 635100, Sichuan Province, China

Corresponding author: Qiao-Li Su, MM, Professor, General Practice Ward, General Practice Medical Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, Chengdu 610041, Sichuan Province, China. 18980601358@163.com

Abstract

BACKGROUND

Hepatitis is a systemic disease that often results in various comorbidities. Metabolic disorders, the most common comorbidities in clinical practice, were selected for this study.

AIM

To investigate the causal relationship between comorbidities and hepatitis treatment outcomes.

METHODS

A total of 23583378 single nucleotide polymorphisms from 1248743 cases and related summaries of genome-wide association studies were obtained from online public databases. A two-sample Mendelian randomization (MR) was performed to investigate causality between exposure [type 2 diabetes mellitus (T2D), hyperlipidemia, and hypertension] and outcome (chronic hepatitis B or C infections).

RESULTS

The data supported the causal relationship between comorbidities and hepatitis infections, which will affect the severity of hepatitis progression and will also provide a reference for clinical researchers. All three exposures showed a link with progression of both hepatitis B (T2D, P = 0.851; hyperlipidemia, P = 0.596; and hypertension, P = 0.346) and hepatitis C (T2D, P = 0.298; hyperlipidemia, P =0.141; and hypertension, *P* = 0.035).

CONCLUSION

The results of MR support a possible causal relationship between different ex-



posures (T2D, hyperlipidemia, and hypertension) and chronic hepatitis progression; however, the potential mechanisms still need to be elucidated.

Key Words: Hepatitis; Comorbidity; Type 2 diabetes mellitus; Hyperlipidemia; Hypertension

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: In our study, the randomization model was well defined for the exposures [type 2 diabetes mellitus (T2D), hyperlipidemia, and hypertension] and outcomes (chronic hepatitis B and chronic hepatitis C) by two-sample Mendelian randomization (MR) analysis, and they showed capabilities for interaction with chronic hepatitis infection. The results of our MR support a possible causal relationship between different exposures (T2D, hyperlipidemia, and hypertension) and chronic hepatitis progression.

Citation: Liang LB, Liu XP, Mao TR, Su QL. Metabolic disorders and hepatitis: Insights from a Mendelian randomization study. World J Gastrointest Surg 2024; 16(6): 1775-1790 URL: https://www.wjgnet.com/1948-9366/full/v16/i6/1775.htm DOI: https://dx.doi.org/10.4240/wjgs.v16.i6.1775

INTRODUCTION

According to the Global Hepatitis Report 2017 by the World Health Organization, more than 1.34 million people died of hepatitis virus infection worldwide in 2015; more than half of the patients died because of progression to cirrhosis and the other half died due to hepatocellular carcinoma[1]. Hepatitis can be caused by infections with different viruses: Hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus. However, only HBV, HCV, and HDV can induce chronic hepatitis, leading to severe cirrhosis and hepatocellular carcinoma^[1]. Because chronic hepatitis is mainly caused by HBV and HCV[2], we investigated the comorbidities of these two types in this study.

HBV is a DNA virus, whereas HCV is an RNA virus. HBV can activate severe immune responses in patients and can be removed by the human body in the short term[3]. However, HBV can also induce a chronic form in the long term; approximately 40% of HBV patients progress to cirrhosis[4], which could be attributable to the long half-life of HBV covalently closed circular DNA[5,6]. Meanwhile, other risk factors such as aging[5], other concomitant diseases, or consumption of alcohol, could significantly increase the probability of being diagnosed with cirrhosis, based on the theory of Sagnelli et al[7]. Similar to HBV, the chances of progression to cirrhosis and hepatocellular carcinoma among patients with HCV infection also increase with age[8]. Other potential risk factors, such as gastrointestinal diseases of the esophagus, stomach, and duodenum (41.7%), could induce comorbidities with hepatitis[9].

Researchers have recently explored the relationship between hepatitis and related comorbidities. According to Hsu et al [10], comorbidities accompanying hepatitis are often caused by hypertension, diabetes, and ischemic heart disease. In addition, circulatory diseases^[9], renal diseases, and non-liver cancers can worsen hepatitis progression accompanied by comorbidities^[8]. Therefore, in this study, we investigated the role of the following typical comorbidities in influencing hepatitis: Type 2 diabetes mellitus (T2D), hyperlipidemia, and hypertension.

As the risk factors and pathology of hepatitis comorbidities vary, analyzing the relationship between clinical treatment and hepatitis progression among different comorbidities becomes challenging. Meanwhile, knowledge in this field is still rather limited; therefore, we employed a Mendelian randomization (MR) protocol to explore this pair of causations. Currently, MR is a widely used research method based on genome-wide association studies (GWAS) and the theory of nucleotide polymorphisms. As a newly developed tool, MR inherits the principles of the equal, random, and independent distribution method, which adopts genetic variants to reveal causal relationships [11,12], thus providing more reliable and authentic results [13,14]. Regarding hepatitis research, MR will help establish the causal linkage between hepatitis comorbidities and disease outcomes. In this study, patients with different comorbidities were regarded as having a functional variation of specific genes, and MR analysis will guide researchers to better understand hepatitis comorbidities and progression.

MATERIALS AND METHODS

Study design

In this study, a two-sample MR analysis was employed to investigate the causal relationship between comorbidities and hepatitis treatment outcomes. Meanwhile, the inverse variance weighting (IVW) method was applied to determine the causal relationship between exposures and outcomes, where comorbidities were regarded as exposures and indicators from various aspects were regarded as outcomes. Consequently, single nucleotide polymorphisms (SNPs) associated with



Baichiden WJGS https://www.wjgnet.com

Table 1 Description of included traits									
Group	Trait	ID	Sample size	Sample size Year		SNPs			
Exposures	T2D	ebi-a-GCST90093109	i-a-GCST90093109 50533		16677/33856	13403040			
	Hyperlipidemia	ebi-a-GCST90090994	9714	2022	3310/6404	592502			
	Hypertension	ebi-a-GCST90038604	484598	2021	129909/354689	9587836			
Outcomes	CHB	ebi-a-GCST90018804	351885	2021	145/351740	19079722			
	CHC	ebi-a-GCST90018805	352013	2021	273/351740	19074546			

T2D: Type 2 diabetes mellitus; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; Chronic hepatitis B; CHC: Chronic hepatitis C.




Figure 1 Mendelian randomization analysis. MR: Mendelian randomization; SNP: Single nucleotide polymorphism.

hepatitis comorbidities were used as instrumental variables, while their clinical conditions were used as outcome variables. Based on this condition, three important assumptions should be satisfied.

Assumption 1: The selected SNPs should be significantly related to the exposure variable. Assumption 2: SNPs should remain independent of factors that could play a role in exposure and outcomes. Assumption 3: SNPs should not have a direct impact on inducing changes in hepatitis status but can only alter the status via comorbidities to exhibit a causal relationship.

Based on the descriptions above, we conducted an MR analysis as depicted in Figure 1.

Data of exposure and outcome

The included SNPs and related GWAS summaries were obtained from the online public databases IEU OpenGWAS (https://gwas.mrcieu.ac.uk/) and FinnGen Biobank (https://r8.finngen.fi/), which provide genetic insights from a wellphenotyped isolated population[15]. Online calculations were performed using the MR-Base platform (http:// app.mrbase.org/, version 1.4.3 8a77eb; accessed on 08 January 2024)[11]. In this study, different pairs of exposures and outcomes were formed to examine their relationships, where T2D (total 50,533 samples, 16677 cases/33856 controls), hyperlipidemia (total 9714 samples, 3310 cases/6404 controls), and hypertension (total 484598 samples, 129909 cases/ 354689 controls) comprised the exposures, and chronic hepatitis B (CHB; total 351885 samples, 145 cases/351740 controls) and chronic hepatitis C (CHC) infections (total 352013 samples, 273 cases/351740 controls). Table 1 lists the characteristics of these pairs. These data were accessed and investigated on 06 January 2024.

MR analysis

MR analysis was deployed to investigate the association between metabolic disorders and chronic hepatitis, which leveraged genetic variants as instrumental variables to infer causal relationships. The MR-base GWAS catalog served as a crucial tool for selecting appropriate SNPs as instrumental variables during the MR analysis. Meanwhile, rigorous criteria



Bishidena® WJGS | https://www.wjgnet.com

were adopted to ensure the high authenticity of the SNP statistics: *P* value threshold of less than 5×10^8 and LD Rsq threshold of 0.001.

Meanwhile, we utilized various models to test the theory that comorbidities affect chronic hepatitis. For instance, the IVW method as a commonly used approach in MR analysis, was used to estimate the causal effect between exposure and outcome. Additionally, the MR-Egger model was utilized to detect and correct for potential horizontal pleiotropy with a non-zero *P* value indicating statistical significance (P < 0.05). To ensure a convincing conclusion, the Cochrane Q test was applied with the IVW and MR-Egger tests to test for heterogeneity.

To verify the robustness of this MR analysis, sensitivity analyses were conducted by using various MR methods, including MR-Egger regression, weighted median, and weighted mode methods. The weighted mode was examined by leave-one-out analysis, where the impact of each instrumental SNP on exposures and outcomes could be detected. In addition, the odds ratio (OR) and its 95% confidence interval (95%CI) were calculated using the MR results to predict the integrity of the causal relationship between exposure and outcome factors.

Presentation of the results was meticulously executed through the creation of comprehensive visualizations, including forest plots, funnel plots, leave-one-out plots, and scatter plots. These plots provided insights into the effects of each SNP on both exposure and outcome variables, facilitating a deeper understanding of the observed associations.

The statistical analyses were conducted using R (version 4.0.3) and R/TwoSampleMR (https://mrcieu.github.io/ TwoSampleMR, version 0.5.5) were used with the online analysis tool for computational efficiency. By employing these rigorous statistical approaches, the study aimed to provide robust evidence regarding the relationship between metabolic disorders and chronic hepatitis, contributing to the broader understanding of disease etiology and potential therapeutic interventions.

RESULTS

MR estimates

We chose three typical comorbidities among patients with chronic hepatitis, namely T2D, hyperlipidemia, and hypertension, as exposure factors and found their GWAS summary for detailed MR. In this study, we found that these factors were significantly associated with the progression of chronic hepatitis. As shown in Table 1, the overall SNP exposure was 23583378 and the total sample accounted for 1248743 cases. In the outcome group, the number of patients with hepatitis B and C infections was 418 of 703898 cases. These data were retrieved from public research worldwide and, therefore, present extensive human research.

Detailed data of the two-sample MR are presented in Table 2. All three exposures exhibited a role in promoting the progress of hepatitis: T2D showed a link with hepatitis B progression examined by IVW (OR = 1.01676, 95%CI = 0.854-1.210, P = 0.851), as did hyperlipidemia (OR = 0.97827, 95%CI = 0.902-1.061, P = 0.596), and hypertension (OR = 1.35243, 95%CI = 0.721-2.535, P = 0.346). For the other outcomes of CHC infection, T2D promoted its progression with OR = 0.94825, 95%CI = 0.858-1.048, P = 0.298; hyperlipidemia with OR = 0.96140, 95%CI = 0.912-1.013, P = 0.141; and hypertension with OR = 0.67301, 95%CI = 0.465-0.973, P = 0.035).

Consistent with the findings in Table 2, the effects of the SNPs on exposure and outcomes are illustrated below (Figure 2).

Sensitivity analyses

As mentioned in the MR section, different statistical models were applied to examine the quality of the analysis. For example, to examine the horizontal pleiotropy of this MR, the MR-Egger intercept was calculated based on the mode with P > 0.05, suggesting a correct scientific basis for this analysis. Directional horizontal pleiotropy was drawn in funnel plots (Figure 3), where the data dots were distributed in a symmetrical form. In addition, no heterogeneity was found in this study because the *P* values were greater than 0.05. Meanwhile, the leave-one-out analysis results indicated a significant relationship between different exposures and outcomes (Figures 4 and 5).

DISCUSSION

Currently, with faster transportation and a changeable lifestyle in modern societies, the probability of a person diagnosed with two or more diseases are increasing[16]. Since the mortality rate for patients with chronic hepatitis remains low, and the situations for the patients carrying an additional disease become complicated, we performed this MR to analyze the potential effects of comorbidities during hepatitis and the disease progression among the patients, and the first category went to cardiovascular disease after we looked up the related findings.

According to our findings, comorbidities associated with metabolic disorders and cardiovascular disease promote the progression of chronic hepatitis. A meta-analysis by Naing *et al*[17], which included 17 studies with 286084 patients demonstrated a strong relationship between T2D and CHC infection. This correlation was first proposed by Allison *et al* [18] in 1994, based on the finding of abnormalities in carbohydrate metabolism, such as glucose intolerance, in cirrhosis. The exact molecular mechanisms remain to be further explored, but MR could help answer this question since the underlying mechanisms are related to genetic specificity[19]. In addition, a meta-analysis found that T2D is associated with hepatitis B infection, and that T2D could promote hepatitis B progression into hepatocellular carcinoma[20]. The pathology remains to be further explored, but studies have indicated that altered microbiome caused by HBV affect both


Outcome		Number of			95%CI	Р	Heter	rogene	ity	Pleiotropy	
	Exposure	Number of instruments	Method	OR		P value	Q	Q_df	Qp	Intercept	P value
CHB infection	T2D	11	MR Egger	1.11338	0.546- 2.271	0.774	6.861	9	0.6516	-0.011	0.803
			Weighted median	1.08022	0.860- 1.357	0.504	-	-	-		
			IVW	1.01676	0.854- 1.210	0.851	6.927	10	0.7323		
			Weighted mode	1.10321	0.815- 1.493	0.576	-	-	-		
	Hyperlipidemia	5	MR Egger	1.00996	0.804- 1.269	0.938	3.888	3	0.2738	-0.013	0.784
			Weighted median	1.00910	0.918- 1.110	0.857	-	-	-		
			IVW	0.97827	0.902- 1.061	0.596	4.004	4	0.4055		
			Weighted mode	1.01660	0.912- 1.133	0.765	-	-	-		
	Hypertension	277	MR Egger	1.845401	0.350- 9.728	0.471	279.1	258	0.1751	-0.0028	0.693
			Weighted median	1.56894	0.604- 4.077	0.346	-	-	-		
			IVW	1.35243	0.721- 2.535	0.346	279.3	259	0.1846		
			Weighted mode	1.81921	0.519- 6.379	0.359	-	-	-		
CHC nfection	T2D	11	MR Egger	1.13338	0.744- 1.726	0.574	9.143	9	0.4242	-0.022	0.414
			Weighted median	0.94250	0.825- 1.077	0.391	-	-	-		
			IVW	0.94825	0.858- 1.048	0.298	9.887	10	0.4504		
			Weighted mode	0.94916	0.810- 1.112	0.550	-	-	-		
	Hyperlipidemia	5	MR Egger	0.89288	0.793- 1.005	0.158	3.222	3	0.3587	0.03	0.274
			Weighted median	0.94627	0.898- 0.997	0.038	-	-	-		
			IVW	0.96140	0.912- 1.013	0.141	5.134	4	0.2738		
			Weighted mode	0.94262	0.891- 0.998	0.108	-	-	-		
	Hypertension	260	MR Egger	0.59067	0.223- 1.566	0.291	289.5	258	0.08644	0.0012	0.777
			Weighted median	0.69088	0.391- 1.220	0.206	-	-	-		
			Inverse variance weighted	0.67301	0.465- 0.973	0.035	289.6	259	0.09284		
			Weighted mode	0.83477	0.408- 1.707	0.617	-	-	-		


MR: Mendelian randomization; IVW: Inverse variance weighting; T2D: Type 2 diabetes mellitus; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C.

Baishideng® WJGS https://www.wjgnet.com



В





-2

MR effect size for 'Type ii diabetes || id:ebi-a-GCST90093109' on 'Chronic hepatitis C inf ection || id:ebi-a-GCST90018805'

-1


ò



Salishideng® WJGS | https://www.wjgnet.com

-3

All - Inverse variance weighted



rs1501908 rs2954031 rs662799 rs2075650 rs780092 All – MR Egger All - Inverse variance weighted -0.2 0.0 0.2

MR effect size for 'Hyperlipidemia || id:ebi-a-GCST90090994' on 'Chronic hepatitis C infection || id:ebi-a-GCST90018805'



С

D

Baisbideng® WJGS | https://www.wjgnet.com



F




Figure 2 Forest plot of the comorbidities. A and B: type 2 diabetes mellitus; C and D: Hyperlipidemia; E and F: Hypertension affecting chronic hepatitis B infection (upper panel) and chronic hepatitis C infection (lower panel). MR: Mendelian randomization.

Baishideng® WJGS | https://www.wjgnet.com






Figure 3 Funnel plot of the comorbidities. A and B: Type 2 diabetes mellitus; C and D: Hyperlipidemia; E and F: Hypertension affecting chronic hepatitis B infection (upper panel) and chronic hepatitis C infection (lower panel). MR: Mendelian randomization.

Saishideng® WJGS | https://www.wjgnet.com


A



В







С



Baishideng® WJGS | https://www.wjgnet.com

Ε

F




Figure 4 Leave one-out plot of the comorbidities. A and B: Type 2 diabetes mellitus; C and D: Hyperlipidemia; E and F: Hypertension affecting chronic hepatitis B infection (upper panel) and chronic hepatitis C infection (lower panel). MR: Mendelian randomization.

Boishideng® WJGS | https://www.wjgnet.com




Figure 5 Scatter plot of the comorbidities. A and B: Type 2 diabetes mellitus; C and D: Hyperlipidemia; E and F: Hypertension affecting chronic hepatitis B infection (upper panel) and chronic hepatitis C infection (lower panel). MR: Mendelian randomization.

WJGS https://www.wjgnet.com

Paishideng®

lipid and glucose metabolism, thus increasing the severity of the chronic hepatitis infection until non-alcoholic fatty liver disease (NAFLD) develops[21]. Multiple studies have revealed that parenteral viral hepatitis can affect insulin resistance in the body, thus increasing the severity of hepatitis progression in patients[22]. Hepatitis infection with comorbid T2D eventually progresses to NAFLD[21,23], hepatic steatosis[24], hepatocarcinoma, and fibrosis[25].

Hyperlipidemia is also a frequently observed comorbidity of chronic hepatitis infections in clinical practice[26]. According to a cohort study of 1927 patients from 2005 to 2015, hyperlipidemia was correlated with hepatitis progression into hepatocarcinoma without cirrhosis[27]. Meanwhile, a new type of HBV infection, occult HBV (HBV DNA-positive, but HBV surface antigen-negative), is more likely to occur in patients with hyperlipidemia[28]. The molecular mechanisms by which hyperlipidemia interacts with hepatitis remain unknown; however, an interesting phenomenon between hyperlipidemia and HBV infection has been reported. Statins, which were originally used to treat hyperlipidemia, have been widely used in clinical hepatitis treatment, and they could reduce the risks of progression to cirrhosis [29] and hepatocarcinoma[30,31].

Hypertension, which shares most instrumental SNPs with hepatitis, exhibits a strong association with hepatitis B and C infections. In clinical research, hypertension has been reported to be a risk factor for HCV patients with severe progression[32], and the overall effect in patients (*e.g.*, ascites) with both hypertension and HCV is dependent on the severity of liver damage[33]. However, if patients receive antihypertensive treatment, they present with a mild viral syndrome upon exposure to HBV infection[34]. Researchers have attempted to explain this relationship, and one recent finding is that among patients with hypertension, the estimated glomerular filtration rate (eGFR) is lower in patients with HCV than those without HCV infection[35]. eGFR and other pathways may link hepatitis progression to hypertension; however, further research is required to support this theory.

In our study, the randomization model was well defined for the exposures (T2D, hyperlipidemia, and hypertension) and outcomes (CHB and CHC) by two-sample MR analysis, and they showed capabilities for interaction with chronic hepatitis infection; however, this study lacks clinical experimental data and other supporting materials to strengthen this theory. However, this shortage does not hinder this finding from being further explored, and as the next step in continued research, in-depth research on both clinical and molecular levels will be conducted to determine the exact molecular mechanisms and pathology of this linkage.

CONCLUSION

The results of our MR support a possible causal relationship between different exposures (T2D, hyperlipidemia, and hypertension) and chronic hepatitis progression; however, the potential mechanisms still need to be elucidated, and more supported data should come together to support the theory that these common comorbidities will surely affect the clinical treatment of chronic hepatitis infections.

ACKNOWLEDGEMENTS

The author thanks to all those who support assistance during the writing of this thesis.

FOOTNOTES

Author contributions: Su QL and Liang LB and Mao TR designed and performed the experiments; Liang LB and Liu XP provided support for data analysis and writing the manuscript; Su QL provided the supervision, resources, discussion, design and peer review process; all the authors have seen and approved the manuscript.

Conflict-of-interest statement: Prof. Su has nothing to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: China

ORCID number: Qiao-Li Su 0000-0002-2251-2520.

S-Editor: Lin C L-Editor: A P-Editor: Chen YX

Raishideng® WJGS | https://www.wjgnet.com

REFERENCES

- 1 World Health Organization. Global hepatitis report 2017. Apr 19, 2017. [cited 30 April 2024]. Available from: https://www.who.int/ publications/i/item/9789241565455
- 2 Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 2016; 16: 509-523 [PMID: 27374637 DOI: 10.1038/nri.2016.69]
- 3 Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol 2010; 22: 443-450 [PMID: 20386453 DOI: 10.1097/BOR.0b013e328338f6df]
- Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, 4 Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98 [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4]
- Zhu JY. Analysis of the correlation between CONUT score and hepatitis B cirrhosis. M.Sc. Thesis, Shandong University. 2023. Available 5 from: https://kns.cnki.net/kcms2/article/abstract?v=BQVG6Ge829Y-qHI3Y5tUWGw8m9QqwGqqup_xu90qFn3ceRLdP2CUfKGZnQ7s_ vjK9dWWGzOfnnAt6mVLuwZ34Qr4c1jgF_YpOfJpheuTFEjV7mh4XYXKwpjLnAanFjIIyY9mygto1_ykLHm3Ms9Cvw=&uniplatform= NZKPT&language=CHS
- 6 Zhang H, Tu T. Approaches to quantifying hepatitis B virus covalently closed circular DNA. Clin Mol Hepatol 2022; 28: 135-149 [PMID: 34674513 DOI: 10.3350/cmh.2021.0283]
- Sagnelli E, Stroffolini T, Mele A, Imparato M, Sagnelli C, Coppola N, Almasio PL. Impact of comorbidities on the severity of chronic 7 hepatitis B at presentation. World J Gastroenterol 2012; 18: 1616-1621 [PMID: 22529690 DOI: 10.3748/wjg.v18.i14.1616]
- Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ; R. E.V.E.A.L.-HCV Study Group. Chronic hepatitis C 8 virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-477 [PMID: 22811301 DOI: 10.1093/infdis/jis385]
- 9 Ruzicka DJ, Tetsuka J, Fujimoto G, Kanto T. Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016. BMC Infect Dis 2018; 18: 237 [PMID: 29793436 DOI: 10.1186/s12879-018-3148-z]
- Hsu PY, Wei YJ, Liang PC, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Huang CI, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin 10 ZY, Huang JF, Chang JM, Yeh ML, Huang CF, Chiu YW, Hwang SJ, Chuang WL, Yu ML. Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. J Gastroenterol Hepatol 2021; 36: 2261-2269 [PMID: 33651428 DOI: 10.1111/jgh.15480]
- 11 Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM, Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018; 7 [PMID: 29846171 DOI: 10.7554/eLife.34408]
- 12 Goto A, Yamaji T, Sawada N, Momozawa Y, Kamatani Y, Kubo M, Shimazu T, Inoue M, Noda M, Tsugane S, Iwasaki M. Diabetes and cancer risk: A Mendelian randomization study. Int J Cancer 2020; 146: 712-719 [PMID: 30927373 DOI: 10.1002/ijc.32310]
- Hartwig FP, Borges MC, Horta BL, Bowden J, Davey Smith G. Inflammatory Biomarkers and Risk of Schizophrenia: A 2-Sample Mendelian 13 Randomization Study. JAMA Psychiatry 2017; 74: 1226-1233 [PMID: 29094161 DOI: 10.1001/jamapsychiatry.2017.3191]
- Lee K, Lim CY. Mendelian Randomization Analysis in Observational Epidemiology. J Lipid Atheroscler 2019; 8: 67-77 [PMID: 32821701 14 DOI: 10.12997/jla.2019.8.2.67]
- 15 Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, Aavikko M, Kaunisto MA, Loukola A, Lahtela E, Mattsson H, Laiho P, Della Briotta Parolo P, Lehisto AA, Kanai M, Mars N, Rämö J, Kiiskinen T, Heyne HO, Veerapen K, Rüeger S, Lemmelä S, Zhou W, Ruotsalainen S, Pärn K, Hiekkalinna T, Koskelainen S, Paajanen T, Llorens V, Gracia-Tabuenca J, Siirtola H, Reis K, Elnahas AG, Sun B, Foley CN, Aalto-Setälä K, Alasoo K, Arvas M, Auro K, Biswas S, Bizaki-Vallaskangas A, Carpen O, Chen CY, Dada OA, Ding Z, Ehm MG, Eklund K, Färkkilä M, Finucane H, Ganna A, Ghazal A, Graham RR, Green EM, Hakanen A, Hautalahti M, Hedman ÅK, Hiltunen M, Hinttala R, Hovatta I, Hu X, Huertas-Vazquez A, Huilaja L, Hunkapiller J, Jacob H, Jensen JN, Joensuu H, John S, Julkunen V, Jung M, Junttila J, Kaarniranta K, Kähönen M, Kajanne R, Kallio L, Kälviäinen R, Kaprio J; FinnGen, Kerimov N, Kettunen J, Kilpeläinen E, Kilpi T, Klinger K, Kosma VM, Kuopio T, Kurra V, Laisk T, Laukkanen J, Lawless N, Liu A, Longerich S, Mägi R, Mäkelä J, Mäkitie A, Malarstig A, Mannermaa A, Maranville J, Matakidou A, Meretoja T, Mozaffari SV, Niemi MEK, Niemi M, Niiranen T, O Donnell CJ, Obeidat ME, Okafo G, Ollila HM, Palomäki A, Palotie T, Partanen J, Paul DS, Pelkonen M, Pendergrass RK, Petrovski S, Pitkäranta A, Platt A, Pulford D, Punkka E, Pussinen P, Raghavan N, Rahimov F, Rajpal D, Renaud NA, Riley-Gillis B, Rodosthenous R, Saarentaus E, Salminen A, Salminen E, Salomaa V, Schleutker J, Serpi R, Shen HY, Siegel R, Silander K, Siltanen S, Soini S, Soininen H, Sul JH, Tachmazidou I, Tasanen K, Tienari P, Toppila-Salmi S, Tukiainen T, Tuomi T, Turunen JA, Ulirsch JC, Vaura F, Virolainen P, Waring J, Waterworth D, Yang R, Nelis M, Reigo A, Metspalu A, Milani L, Esko T, Fox C, Havulinna AS, Perola M, Ripatti S, Jalanko A, Laitinen T, Mäkelä TP, Plenge R, McCarthy M, Runz H, Daly MJ, Palotie A. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 2023; 613: 508-518 [PMID: 36653562 DOI: 10.1038/s41586-022-05473-8]
- Nettleton S. The sociology of health and illness. [cited 30 April 2024]. Available from: https://www.wiley.com/en-us/The+Sociology+of+ 16 Health+and+Illness%2C+4th+Edition-p-9781509512737
- Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J 17 Gastroenterol 2012; 18: 1642-1651 [PMID: 22529694 DOI: 10.3748/wjg.v18.i14.1642]
- 18 Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-1139 [PMID: 7699240 DOI: 10.1016/S0168-8278(05)80631-2]
- Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol 2009; 15: 1537-1547 [PMID: 19340895 DOI: 19 10.3748/wjg.15.1537
- 20 Tan Y, Wei S, Zhang W, Yang J, Yan L. Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review. Cancer Manag Res 2019; 11: 705-713 [PMID: 30679924 DOI: 10.2147/CMAR.S188238
- Han W, Huang C, Ji Y, Zhou L, Chen J, Hou J. Alterations in the Gut Microbiota and Hepatitis-B-Virus Infection in Southern Chinese Patients 21 With Coexisting Non-Alcoholic Fatty Liver Disease and Type-2 Diabetes Mellitus. Front Med (Lausanne) 2021; 8: 805029 [PMID: 34993216 DOI: 10.3389/fmed.2021.805029]
- 22 Merza MA. Seroprevalence and risk factors of hepatitis B and C viruses among diabetes mellitus patients in Duhok province, Iraqi Kurdistan.



WJGS | https://www.wjgnet.com

J Family Med Prim Care 2020; 9: 642-646 [PMID: 32318396 DOI: 10.4103/jfmpc.jfmpc_1158_19]

- Zhu L, Jiang J, Zhai X, Baecker A, Peng H, Qian J, Zhou M, Song C, Zhou Y, Xu J, Liu H, Hang D, Hu Z, Shen H, Zhang ZF, Zhu F. 23 Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study. Liver Int 2019; 39: 70-80 [PMID: 30025200 DOI: 10.1111/liv.13933]
- Yu MW, Lin CL, Liu CJ, Huang YW, Hu JT, Wu WJ, Wu CF. Hepatic steatosis and development of type 2 diabetes: Impact of chronic 24 hepatitis B and viral specific factors. J Formos Med Assoc 2022; 121: 1478-1487 [PMID: 34764005 DOI: 10.1016/j.jfma.2021.10.014]
- Mak LY, Hui RW, Lee CH, Mao X, Cheung KS, Wong DK, Lui DT, Fung J, Yuen MF, Seto WK. Glycemic burden and the risk of adverse 25 hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes. Hepatology 2023; 77: 606-618 [PMID: 36130882 DOI: 10.1002/hep.32716]
- 26 Wang X, Xie Q. Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis. J Clin Transl Hepatol 2022; 10: 128-133 [PMID: 35233381 DOI: 10.14218/JCTH.2021.00200]
- 27 Phan J, Ng V, Sheinbaum A, French S, Choi G, El Kabany M, Durazo F, Saab S, Tong M, Busuttil R, Han SH. Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis. J Clin Gastroenterol 2019; 53: 309-313 [PMID: 29912756 DOI: 10.1097/MCG.000000000001062]
- Yang L, Li T, Li W, Tang X, Li J, Long R, Fu Y, Allain JP, Li C. Occult Hepatitis B Virus Infection in Hyperlipidemia Patients. Tohoku J Exp 28 Med 2017; 241: 255-261 [PMID: 28381700 DOI: 10.1620/tjem.241.255]
- Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, Lu CL. Statins decrease the risk of decompensation in hepatitis B virus- and 29 hepatitis C virus-related cirrhosis: A population-based study. *Hepatology* 2017; 66: 896-907 [PMID: 28318053 DOI: 10.1002/hep.29172]
- 30 Goh MJ, Sinn DH, Kim S, Woo SY, Cho H, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Hepatology 2020; 71: 2023-2032 [PMID: 31556128 DOI: 10.1002/hep.30973]
- 31 Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med 2019; 171: 318-327 [PMID: 31426090 DOI: 10.7326/M18-2753]
- 32 Fujinaga K, Usui M, Yamamoto N, Ishikawa E, Nakatani A, Kishiwada M, Mizuno S, Sakurai H, Tabata M, Isaji S. Hypertension and hepatitis C virus infection are strong risk factors for developing late renal dysfunction after living donor liver transplantation: significance of renal biopsy. Transplant Proc 2014; 46: 804-810 [PMID: 24767353 DOI: 10.1016/j.transproceed.2013.11.103]
- Valla D, Flejou JF, Lebrec D, Bernuau J, Rueff B, Salzmann JL, Benhamou JP. Portal hypertension and ascites in acute hepatitis: clinical, 33 hemodynamic and histological correlations. Hepatology 1989; 10: 482-487 [PMID: 2777210 DOI: 10.1002/hep.1840100414]
- Parrilli G, Manguso F, Orsini L, Coccoli P, Vecchione R, Terracciano L, De Luca N, Cirillo N, Abazia C, Budillon G, Marchesini G. Essential 34 hypertension and chronic viral hepatitis. Dig Liver Dis 2007; 39: 466-472 [PMID: 17369113 DOI: 10.1016/j.dld.2007.01.009]
- Gantumur G, Batsaikhan B, Huang CI, Yeh ML, Huang CF, Lin YH, Lin TC, Liang PC, Liu TW, Lee JJ, Lin YC, Lin IL, Huang JF, Chuang 35 WL, Yu ML, Tu HP, Dai CY. The association between hepatitis C virus infection and renal function. J Chin Med Assoc 2021; 84: 757-765 [PMID: 34074934 DOI: 10.1097/JCMA.000000000000561]



WJGS | https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

